Literature DB >> 2985476

Endometrial "sarcomas" complicating ovarian thecoma, polycystic ovarian disease and estrogen therapy.

M F Press, R E Scully.   

Abstract

Unopposed endogenous and exogenous estrogenic stimulation has been considered by most investigators to have a role in the pathogenesis of carcinoma of the endometrium. Although a few cases of "sarcomas" of the endometrium that had developed in an estrogenic setting have been reported, a clear-cut association between estrogenic stimulation and these forms of endometrial cancer has not been established. We report six cases of endometrial sarcomas complicating ovarian thecomas, polycystic ovarian disease, or prolonged estrogen therapy. Three ovarian thecomas, which are considered to be estrogenic tumors, were associated with endometrial malignant mullerian mixed tumor, mullerian adenosarcoma, and low-grade stromal sarcoma in postmenopausal women. Polycystic ovarian disease, a condition characterized by unopposed estrinism due to the peripheral conversion of excessive androstenedione to estrone, was found in a 27-year-old infertile woman with an endometrial malignant mullerian mixed tumor. A pure osteogenic sarcoma of endometrial stromal origin developed in a 28-year-old woman with gonadal dysgenesis (Turner's syndrome) who had received estrogens for 18 years. The sixth woman, with an empty sella turcica after radiation therapy of a pituitary adenoma, had an endometrial mullerian adenosarcoma at the age of 40 years after 16 years of estrogen therapy. None of these patients had had pelvic radiation therapy. The evidence from this series of cases and from six additional cases identified in the literature suggests that the risk of endometrial sarcomas may be increased by estrogen therapy or endogenous disorders that lead to unopposed estrogenic stimulation of the uterus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985476     DOI: 10.1016/0090-8258(85)90246-x

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Malignant neoplasms of decidual origin (deciduosarcomas) induced by estrogen-progestin-releasing intravaginal devices in rabbits.

Authors:  B C Zook; I Spiro; R Hertz
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

Review 2.  Uterine Adenosarcoma: a Review.

Authors:  Michael J Nathenson; Vinod Ravi; Nicole Fleming; Wei-Lien Wang; Anthony Conley
Journal:  Curr Oncol Rep       Date:  2016-11       Impact factor: 5.075

3.  Correlations between reduced expression of the metastasis suppressor gene KAI-1 and accumulation of p53 in uterine carcinomas and sarcomas.

Authors:  Juliane Briese; Heinrich M Schulte; Maria Sajin; Christoph Bamberger; Katja Redlin; Karin Milde-Langosch; Thomas Löning; Ana-Maria Bamberger
Journal:  Virchows Arch       Date:  2008-04-16       Impact factor: 4.064

Review 4.  Cervical Mullerian adenosarcoma with heterologous sarcomatous overgrowth: a fourth case and review of literature.

Authors:  Tito Silvio Patrelli; Salvatore Gizzo; Stefania Di Gangi; Giorgia Guidi; Mario Rondinelli; Giovanni Battista Nardelli
Journal:  BMC Cancer       Date:  2011-06-11       Impact factor: 4.430

5.  Leiomyosarcoma of the Oropharynx and Neurogenic Tumors in a Young Patient With Turner's Syndrome.

Authors:  A De Chiara; G Apice; G Silvestro; S Losito; G Botti; F Ionna; V De Rosa; A Borghese; V Ninfo
Journal:  Sarcoma       Date:  2001

6.  Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas.

Authors:  O Reich; S Regauer; W Urdl; M Lahousen; R Winter
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

Review 7.  Gynaecological cancers and leptin: A focus on the endometrium and ovary.

Authors:  A Ray; J Fornsaglio; S Dogan; S Hedau; D Naik; A De
Journal:  Facts Views Vis Obgyn       Date:  2018-03

Review 8.  Update on Endometrial Stromal Tumours of the Uterus.

Authors:  Iolia Akaev; Chit Cheng Yeoh; Siavash Rahimi
Journal:  Diagnostics (Basel)       Date:  2021-03-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.